Sabcomeline Explained

Sabcomeline (Memric; SB-202,026) is a selective M1 receptor partial agonist that was under development for the treatment of Alzheimer's disease.[1] It made it to phase III clinical trials before being discontinued due to poor results.

See also

Notes and References

  1. Loudon JM, Bromidge SM, Brown F, etal . SB 202026: a novel muscarinic partial agonist with functional selectivity for M1 receptors . The Journal of Pharmacology and Experimental Therapeutics . 283 . 3 . 1059–68 . December 1997 . 9399977 .

This article is licensed under the GNU Free Documentation License. It uses material from the Wikipedia article "Sabcomeline".

Except where otherwise indicated, Everything.Explained.Today is © Copyright 2009-2024, A B Cryer, All Rights Reserved. Cookie policy.